Your browser doesn't support javascript.
loading
Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.
Callegari, Ernesto; Lin, Jian; Tse, Susanna; Goosen, Theunis C; Sahasrabudhe, Vaishali.
Affiliation
  • Callegari E; Department of Medicine Design-Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA.
  • Lin J; Department of Medicine Design-Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA.
  • Tse S; Department of Medicine Design-Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA.
  • Goosen TC; Department of Medicine Design-Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA.
  • Sahasrabudhe V; Department of Clinical Pharmacology, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA.
CPT Pharmacometrics Syst Pharmacol ; 10(2): 127-136, 2021 02.
Article in En | MEDLINE | ID: mdl-33314761

Full text: 1 Database: MEDLINE Main subject: Mefenamic Acid / Cyclooxygenase Inhibitors / Glucuronosyltransferase / Bridged Bicyclo Compounds, Heterocyclic / Sodium-Glucose Transporter 2 Inhibitors Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2021 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Mefenamic Acid / Cyclooxygenase Inhibitors / Glucuronosyltransferase / Bridged Bicyclo Compounds, Heterocyclic / Sodium-Glucose Transporter 2 Inhibitors Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2021 Type: Article Affiliation country: United States